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We conclude that the prothrombin gene variant probably increases the risk of VOD in BMT patients. Identification of high risk patients may allow early detection of events leading to VOD, and early intervention and treatment of this disease. However, it is interesting that the more common thrombophilic trait, FV Leiden, does not appear to be a predisposing factor for VOD. We recognise that the number of patients in our preliminary study is small and therefore would suggest our findings warrant further studies.
C Duggan
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Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures
Pericentric inversion of chromosome 16 [inv(16)(p13q22)] and the related t(16;16)(p13;q22), 1 resulting in a chimeric fusion of the CBF␤ and MYH11 genes, are seen in a subset of acute myeloid leukemia (AML) patients. [2] [3] [4] The molecular marker is detectable by reverse transcription-polymerase chain reaction assay (RT-PCR) [5] [6] [7] [8] [9] on RNA at the time of diagnosis, and could be particularly useful for monitoring MRD in patients who achieve complete clinical remission (CCR) after induction therapy. [10] [11] [12] [13] Marcucci et al 14 and several other authors [10] [11] [12] [13] have reported favorable clinical outcomes despite persistence of CBF␤/MYH11 transcripts detected by RT-PCR; similar findings have been reported for another core-binding-factor altered in AML, 15, 16 in which positive expression of AML1-ETO transcript can persist after induction and consolidation chemotherapy without evidence of hematological relapse. Thus, the definition of 'molecular' remission and its significance in terms of relapse risk require further investigation.
14 Following the assumption that in such an aggressive pathology it is preferable to obtain CCRs with 'PCR negativity', we reviewed our series of 19 AML patients with inv(16) translocation to assess whether instances of PCR positivity could have been caused by differences in chemotherapy protocols or bone marrow transplantation (BMT) procedures.
In all cases, our PCR strategy, RNA isolation and RT-PCR procedure were performed as described. 5, 6 Experiments using inv(16) RNA in serial dilution of total RNA from normal individuals were also conducted: the level of sensitivity of type A fusion sequence amplification after nested PCR was of 1 tumor cell in 10 (16) is strictly associated with the type A transcript. 6, 7 Three patients (Nos 1-3 in Table 1 ), who were only treated with non-ablative chemotherapy due to their age, died from AML: in these cases MRD was not evaluated. The remaining 16 patients (Nos 4-19) achieved CCR after different schedules of ablative induction and consolidation chemotherapy protocols ( Table 1) . Fifteen of these patients also achieved PCR negativity at the end of consolidation chemotherapy. The remaining patient (No. 4) relapsed with clonal evolution after 3 months from diagnosis and died of leukemia (no MRD assessment was possible). All 15 patients who achieved PCR negativity are currently alive in first (12 cases) or second (three cases) CCR (median overall survival 34 months; range 3-90 months) (Figure 1 ), confirming that AML with inv (16) is curable by ablative therapy in a high percentage of cases.
Of the 15 patients who achieved PCR negativity, 11 were further consolidated with BMT as follows: three received allogeneic BMT from an HLA-identical sibling, and eight underwent autologous BMT (ABMT). 17 Among the latter, three ABMTs (patient Nos 9, 10, 14) were performed with peripheral blood stem cells (PBSC) collected 18 at the end of consolidation, after G-CSF stimulation and five (patient Nos 5, 6, 12, 13, 18) with unpurged bone marrow stem cells. The other four patients were consolidated with one or two courses of chemotherapy alone (FLANG schedule) 19 and are pending ABMT procedures. Twelve patients have remained in first CCR with PCR negativity (median disease-free survival 26 months; range 1-51 months).
As regards the relationship between BMT procedure and MRD status, all three patients (Nos 7, 8 and 11 in Table 1 ) who underwent an allogeneic BMT from an HLA-identical sibling while in first CCR achieved PCR negativity and have remained disease-free. Among the eight patients who received ABMT, three (Nos 14, 9, 13) relapsed at 14, 27 and 28 months from diagnosis and after 6, 20 and 22 months from ABMT. In two cases (patient Nos 9 and 13), no prediction of re-emerging MRD was possible, due to the fact that PCR was last performed 8 and Ͼ12 months, respectively before relapse. The other patient (No. 14), after a second consolidation chemotherapy course, was recorded as transitory double PCR negativity, but showed persistent PCR positivity in bone marrow samples during all subsequent phases of his clinical follow-up: at 4, 6, 9 and 12 months when he had cytogenetic and then clinical relapse ( Figure 1 ). All three patients subsequently received reinduction chemotherapy. In all cases a second CCR (in two cases, Nos 9 and 13 also with PCR negativity) was reached, and in patient No. 13 this was long lasting (+90 months). It is noteworthy that patient No. 14 had an additional chromosomal +9 on his karyotype analysis. Furthermore, patient No. 9, who was treated with an induction course of ICE protocol 20 and obtained a CCR with PCR negativity, had severe pulmonary infection during the neutropenic period and a life-threatening course. She was later consolidated with the NOVIA chemotherapy schedule 20 and then underwent ABMT with PBSC. After 20 months she relapsed and was re-induced with two courses of FLANG schedule chemotherapy. She obtained a second CCR, which lasted 7 months. These findings suggest that in this leukemic subtype a second CCR may be obtained by reinduction chemotherapy in a very high percentage of cases.
By contrast, all the available bone marrow collections obtained at the end of consolidation chemotherapy and before ABMT in the five patients (Nos 5, 6, 10, 12, 18) who did not relapse were persistently PCR negative. Thus, whereas four out of the five patients who underwent ABMT with BM had no further evidence of disease, the two patients who were grafted with PBSC relapsed and one had evidence of MRD in the graft (Figure 1 ). Thus, although we cannot draw a firm conclusion, we suspect that the PBSC could be more contaminated than bone marrow. In contrast to the preliminary results of other authors, 9 our PCR results suggest that the use of G-CSF might recruit this type of leukemic progenitor cell. This concept is supported by a preliminary observation of an in vitro proliferative effect of G-CSF on AML blasts. 21 Thus, we now prefer to avoid the use of G-CSF for bone marrow mobilization procedures.
In conclusion, we confirm that the majority of our patients treated with ablative chemotherapy obtained CCR, most of them with PCR negativity, and we think that use of G-CSF in PBSC harvested for ABMT is inappropriate in these patients as it may actually lead to relapse. The small population size and limited number of patients in each category of allogeneic or autologous bone marrow or PBSC transplantation preclude any definitive conclusions about the role of transplantation.
Finally, we stress the importance of an accurate MRD assessment to modulate post-remission treatment modalities in accordance with the risk of relapse.
G Martinelli
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Use of selected CD34
+ cells in the treatment of relapsed Hodgkin's lymphoma Autologous stem cell transplantation has become a routine method in the treatment of relapsing Hodgkin's disease. However, the long-term survival is between 35 and 45%. 1, 2 One of the possible explanations may be the infusion of tumor cells in the graft after high-dose chemotherapy. It has been shown that peripheral blood stem collections contain Hodgkin's cells. 3 Here we show the use of selected stem cells (CD34 + ) for autografting after high-dose chemotherapy.
Between April 1996 and April 1998 10 patients with Hodgkin's disease were autografted at our Institute with positively selected CD34 + cells (Ceprate SC). The main characteristics of the patients before transplantation are shown in Table 1 . As one can see all of the patients were heavily pretreated, all were in 2nd or higher CR (PR). This fact is reflected in Table 2 by the amounts of CD34 + cells per kg of body weight. Only two patients reached the minimal recommended number of CD34 + cells. Nevertheless, all patients engrafted successfully and we were never obliged to use the backup bag.
The median of 16 days to reach neutrophils Ͼ0.5 × 10 9 /l under these circumstances is a reflection of the number of CD34 + cells used. One of the 10 patients relapsed in the liver after 10 months was irradiated, relapsed and is now
